Avidity Biosciences, based in San Diego, has aligned with the FDA regarding its product approval pathways. Mike Maclean serves as the company's CFO.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Avidity Biosciences, based in San Diego, has aligned with the FDA regarding its product approval pathways. Mike Maclean serves as the company's CFO.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Avidity Biosciences, based in San Diego, has aligned with the FDA regarding its product approval pathways. Mike Maclean serves as the company's CFO.Sub-event
Avidity aligned with FDA on approval pathways, with Mike Maclean as CFO, operating from San Diego.1 source
Keep exploring
The entities involved
Related events
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Coverage
Newest first; wire copies grouped- PR NewswireAvidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data fr